As shown in Figure 1A and Figure 2A, 75% of KRAS-mutant NSCLC cell lines evaluated were sensitive to combined eIF4A and RAS pathway inhibitors, although a subset were resistant. Here, KRAS is linked to non-small cell lung carcinoma.